Citius Pharmaceuticals, Inc. CTXR

Company Overview

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical and biopharmaceutical company focused on the development and commercialization of critical care products, oncology therapies, and anti-infective treatments. The company operates within the biotechnology and pharmaceutical industries, with a strategy centered on advancing late-stage or differentiated therapeutic candidates that address unmet medical needs in hospital, oncology, and specialty care settings. Its primary value drivers have included product development programs targeting severe infections, stem-cell therapy applications, and oncology-related supportive care products.

The company was founded in 2007 by industry veterans with backgrounds in pharmaceutical commercialization and drug development. Over time, Citius evolved from a development-stage specialty pharmaceutical company into a broader biopharmaceutical platform pursuing both small-molecule and cell-therapy opportunities. Key development programs have included Mino-Lok, a catheter lock solution intended to salvage infected central venous catheters, and oncology-focused assets associated with its subsidiary structure. Public filings and company disclosures indicate that Citius has emphasized regulatory advancement, licensing opportunities, and strategic partnerships as central components of its growth model.